The global gene therapy market size was estimated at USD 5.54 billion in 2023 and is projected to grow at a CAGR of 18.88% from 2024 to 2030. The market growth is attributed to many factors such as the expanding area of advanced therapies along with gene delivery technologies and progressive competition among key players focused on commercialization of their therapies. The biotechnology companies are investing in acquisitions, mergers/collaborations, and deals as a key strategy to increase in-house expertise and strengthen the product pipelines.

The COVID-19 outbreak has negatively impacted the market growth. This sector has experienced severe disruption due to COVID-19, which has historically presented significant challenges in the supply of materials, manufacturing, and logistics operations. For instance, companies had lengthy delivery times for specific components. They later discovered that it was short on clinical trial supplies when a partner contract manufacturing company was compelled to shut down.

Gather more insights about the market drivers, restrains and growth of the Global Gene Therapy Market 

Gene Therapy Market Report Highlights

• The AAV segment shows a significant revenue contribution of 22% in 2023. Several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy product.
• By indication, the spinal muscular atrophy (SMA) segment dominated the market in 2023 with a share of 46.8%. Although SMA is a rare disorder, it is one of the most common fatal inherited diseases of infancy.
• The Beta-Thalassemia Major/SCD segment is anticipated to register the fastest CAGR of 38.3% over the forecast period. Gene therapy for SCD and β-thalassemia is based on transplantation of gene-modified hematopoietic stem cells.
• North America dominated the market in 2023 with the largest revenue share of 65.2% in 2023. This region is expected to become the largest routine manufacturer of gene therapy in terms of the number of approvals and revenue generated during the forecast period.
• Europe is estimated to be the fastest-growing regional segment from 2024 to 2030. This is attributed to its large population with unmet medical needs and increasing demand for novel technologies in the treatment of rare but increasingly prevalent diseases.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global peptide synthesis market size was valued at USD 608.0 million in 2023 and is projected to grow at a CAGR of 12.7% from 2024 to 2030.
• The global molecular methods for food safety testing market size was valued at USD 2.41 billion in 2023 and is projected to grow at a CAGR of 8.9% from 2024 to 2030. 

Segments Covered in the Report

Grand View Research has segmented the global gene therapy market report based on indication, vector type, route of administration, and region:

Gene Therapy Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Large B-Cell Lymphoma
• Multiple Myeloma
• Spinal Muscular Atrophy (SMA)
• Acute Lymphoblastic Leukemia (ALL)
• Melanoma (lesions)
• Inherited Retinal Disease
• Beta-Thalassemia Major/SCD
• Others

Gene Therapy Vector Type Outlook (Revenue, USD Million, 2018 - 2030)

• Lentivirus
• RetroVirus gamma RetroVirus
• AAV
• Modified Herpes Simplex Virus
• Adenovirus
• Others

Gene Therapy Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Intravenous
• Others

Gene Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • Switzerland
• Asia Pacific
  • Japan
  • China
  • South Korea
  • Australia
• Rest of the world 

Order a free sample PDF of the Gene Therapy Market Intelligence Study, published by Grand View Research.